Non-Hodgkin's Lymphoma
Hyperfractionated Dual Equivalent Fractionated (HyDEF) Bridging Radiation Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Undergoing T-Cell Redirection Therapy
Volunteers
Health Professionals
What is the purpose of this trial?
This study evaluates the feasibility and safety of a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Amy Pugliese, APRN
- Carolyn Demsky, APRN
- Daniel Hicks, MD
- Francine Foss, MD
- Iris Isufi, MD
- James Laird, MD
- Kenneth B. Roberts, MD
- Kevin Du, MD, PhD, MSCI
- Lisa Rivera, APRN
- Lohith Gowda, MD, MRCP
- Meifeng Shen, PA
- Noffar Bar, MD
- Scott Huntington, MD, MPH, MSc
- Shalin Kothari, MD
- Stephanie Kacik, APRN
- Stuart Seropian, MD
- Last Updated01/11/2026
- Study HIC#2000038092